May 2025
An Investigational Drug for Treatment of C3G and Primary IC-MPGN
A Pre-Approval Information Exchange (PIE) Webinar sponsored by Apellis Pharmaceuticals, Inc.
C3G and Primary IC-MPGN are 2 rare, chronic glomerular diseases that are driven by complement system overactivation and lead to severe kidney damage. Review of the results of the VALIANT Phase 3 trial, evaluating pegcetacoplan as an investigational product for use in C3G and IC-MPGN. The safety and efficacy of pegcetacoplan in C3G and IC-MPGN have not been established.
This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.
This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.
May 2025
Northwest AMCP Day of Education 2025
Join the Northwest AMCP Affiliate for a Day of Education!
May 2025
Ohio-Kentucky AMCP Day of Education 2025
Join the Ohio-Kentucky AMCP Affiliate for a Day of Education!
May 2025
AMCP Market Insights: Webinar on ER+/HER2- Metastatic Breast Cancer Part 2
Join us for a webinar on ER+/HER2- Metastatic Breast Cancer, a disease affecting nearly 150,000 people in the U.S. Despite advancements in treatment, significant gaps remain in access, affordability, and comprehensive care. This session will feature a clinical key opinion leader and payer participants from the roundtable convened by AMCP in February 2025. Presenters will characterize the clinical and QOL burden of ER+/HER2, explore the mechanisms of action of current therapies, review current treatment options, describe therapeutics that targets ERs, and outline payer strategies to facilitate precision oncology care.
May 2025
eLearning Day: Focus on Cell and Gene Therapy
AMCP eLearning Day is an educational experience focused on the hottest topics related to aging. This is an opportunity to learn live from expert faculty while earning CPE from home. The live event consists of two 1-hour virtual sessions held on May 14. These sessions will be recorded and converted to enduring activities on AMCP Learn by May 21.
MEMBERS
NON-MEMBERS
May 2025
An Investigational RNA-Targeted Long-Term Prophylactic Medicine for Hereditary Angioedema (HAE)
A Pre-Approval Information Exchange (PIE) Webinar sponsored by Ionis Pharmaceuticals, Inc.
This presentation includes information about a novel and investigational RNA-targeted long-term prophylactic
treatment option for hereditary angioedema (HAE) and provides the following:
• Overview of HAE, including the clinical and economic burdens experienced by patients and
healthcare systems
• Review of efficacy and safety data from the pivotal and open-label extension clinical trials
This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.
This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.
May 2025
AMCP Legislative Days 2025
AMCP Legislative Days is the flagship federal advocacy event for managed care pharmacy professionals. Attendees meet with their Members of Congress and their staff, to advocate for policies that provide patients with the medicine they need at a cost they can afford. Advocates in attendance will garner support for AMCP’s top policy priorities: the Access to Prescription Digital Therapeutics Act, the Medicaid VBPs for Patients (MVP) Act, and the Equitable Community Access to Pharmacist Services Act. Attendees also receive invitations to the 2025 AMCP Capitol Dinner and Reception, where AMCP honors its congressional champions for advancing the practice of managed care pharmacy. Attendance in 2025 is by invitation only. Learn ways to become a member and take action and advocate on AMCP policy and advocacy issues.
Key Note Session: Health Care and the Judiciary (1.00 hours ACPE Credit Available)
Tuesday, May 13 from 11:00am – 12:00pm ET.
Attendance is by invitation only.
Registration for AMCP Legislative Days 2025 is now closed. For more information on AMCP Legislative Days 2026, please contact Tyler Thorne (tthorne@amcp.org)
MEMBERS
May 2025
AMCP New Member Orientation Event
Save the Date! Join us for a new member orientation where you'll connect with fellow members, learn about AMCP key priorities, explore key resources, discover volunteer opportunities, and get your questions answered in real-time. We’re here to help you make the most of your membership from day one! This event is open to first-year members and we encourage you to attend an orientation event during your first 6 months as a member.
MEMBERS
May 2025
Optimizing Healthcare Outcomes: Clinical Advancements, Economic Impact of RYONCIL® in Treating Pediatric SR-aGVHD
A Science & Innovation Webinar, presented by Mesoblast.
Join us for an insightful webinar on the advancements in treating pediatric steroid-refractory acute versus host disease (SR-aGVHD) with RYONCIL®, which was approved by the FDA on December 19, 2024. We will delve into the significant unmet need in SR-aGVHD, a condition with high morbidity and mortality rates, and how Ryoncil’s safety and efficacy offers a promising new therapeutic option that has significant impact on long-term survival outcomes. We will also explore the potential to deliver significant healthcare cost savings due to substantial long-term survival benefits, utilizing health economic models for ultra-rare diseases and high-impact therapies.
April 2025
AMCP Market Insights: Webinar on ER+/HER2- Metastatic Breast Cancer
An AMCP Market Insights Webinar.
Join us for a webinar on ER+/HER2- Metastatic Breast Cancer, a disease affecting nearly 150,000 people in the U.S. Despite advancements in treatment, significant gaps remain in access, affordability, and comprehensive care. This session will feature a clinical key opinion leader and payer participants from the roundtable convened by AMCP in February 2025. Presenters will characterize the clinical and QOL burden of ER+/HER2, explore the mechanisms of action of current therapies, review current treatment options, describe therapeutics that targets ERs, and outline payer strategies to facilitate precision oncology care.